IP Library › Granted Patent US 12,286,489
Granted Patent B2
US 12,286,489 · App. 17/652,557 · Granted Apr 29, 2025

Modified antigen binding polypeptide constructs and uses thereof

Inventors: Mario Sanches (Vancouver, CA); Thomas Spreter Von Kreudenstein (Vancouver, CA); Dunja Urosev (Vancouver, CA); Stacey A. L. Tom-Yew (Vancouver, CA); Adam Louis Corper (Vancouver, CA); Igor Edmondo Paolo D'Angelo (Vancouver, CA); Yang-Chieh Chou (Vancouver, CA); Surjit Bhimarao Dixit (Vancouver, CA)
Assignee: Zymeworks BC, Inc.
C07K16/468C07K16/2863C07K16/32C07K16/36C07K2317/21C07K2317/24C07K2317/31C07K2317/51C07K2317/52C07K2317/522C07K2317/55C07K2317/56C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,286,489
App. No.
17/652,557
Granted
Apr 29, 2025
Kind
B2
Abstract

The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C H1 and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.

Claims (145)

1. An antigen binding polypeptide construct comprising at least a first heterodimer and a second heterodimer,

the first heterodimer comprising a first human or humanized immunoglobulin G (IgG) heavy chain polypeptide sequence (H1), and a first human or humanized immunoglobulin kappa light chain polypeptide sequence (L1), and binding to a first epitope; and the second heterodimer comprising a second human or humanized immunoglobulin G (IgG) heavy chain polypeptide sequence (H2), and a second human or humanized immunoglobulin kappa light chain polypeptide sequence (L2), and binding to a second epitope, wherein the H1 and L1 polypeptide sequences of the first heterodimer are different from the corresponding H2 and L2 polypeptide sequences of the second heterodimer,

wherein H1 and H2 each comprise a heavy chain variable domain (VH domain) and a heavy chain constant domain (CH1 domain);

wherein L1 and L2 each comprise a light chain variable domain (VL domain) and a light chain constant domain (CL domain);

wherein H1, H2, L1, and L2 comprise the following amino acid substitutions that promote preferential pairing of H1 with L1 as compared to L2, and of H2 with L2 as compared to L1, at positions identified according to the Kabat numbering system:

a) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 178E;

b) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

c) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 178E and 180E;

d) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

e) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

f) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

g) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

h) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

i) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

j) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E, 160E and 178E;

k) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

l) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E, 178E and 180E;

m) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 178E;

n) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

o) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 178E;

p) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

q) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

r) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

s) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

t) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

u) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

v) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

w) H1 comprises amino acid substitutions 143D, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

x) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

y) H1 comprises amino acid substitutions 143D, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

z) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

aa) H1 comprises amino acid substitutions 143D, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

bb) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

cc) H1 comprises amino acid substitutions 143E and 145T, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

dd) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E, 180E;

ee) H1 comprises amino acid substitutions 143E and 145T, L1 comprises amino acid substitutions 124R, 160K and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

ff) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

gg) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E and 180E;

hh) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E, 160E and 180E;

ii) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E and 180E;

jj) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 186R, and L2 comprises amino acid substitutions 124E, 160E and 180E;

kk) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution Q179R, and L2 comprises amino acid substitutions 124E and 178E;

ll) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution Q179R, and L2 comprises amino acid substitutions 124E, 160E and 178E;

mm) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 178E;

nn) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179R, and L2 comprises amino acid substitutions 124E, 178E and 180E;

oo) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 178E;

pp) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 180E;

qq) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

rr) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 178E and 180E;

ss) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

tt) H1 comprises amino acid substitutions 139C, 143E, 145T, and 179E, L1 comprises amino acid substitutions 116C, 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

uu) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

vv) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

ww) H1 comprises amino acid substitutions 143D, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

xx) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

yy) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

zz) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

aaa) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R, 160K, and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

bbb) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

ccc) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124K and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

ddd) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R, 160K, and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

eee) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

fff) H1 comprises amino acid substitutions 143E, 145T, and 179D, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

ggg) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178K, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E;

hhh) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitution 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E;

iii) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 143K, and L2 comprises amino acid substitutions 124E and 133D; or

jjj) H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 143R, and L2 comprises amino acid substitutions 124E and 133E,

wherein when both L1 and L2 are co-expressed with at least one of H1 and H2, the amount of H1-L1 compared to H1-L2 and the amount of H2-L2 compared to H2-L1 is greater than the amount of H1-L1 compared to H1-L2 and the amount of H2-L2 compared to H2-L1 in the absence of the amino acid substitutions.

2. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E and 180E.

3. The antigen binding polypeptide construct of claim 2 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer, and wherein the Fc is a human Fc.

4. The antigen binding polypeptide construct of claim 3 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

5. The antigen binding polypeptide construct of claim 4 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

6. The antigen binding polypeptide construct according to claim 2 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

7. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 179R, and L2 comprises amino acid substitutions 124E, 178E and 180E.

8. The antigen binding polypeptide construct of claim 7 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer, and wherein the Fc is a human Fc.

9. The antigen binding polypeptide construct of claim 8 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

10. The antigen binding polypeptide construct of claim 9 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

11. The antigen binding polypeptide construct according to claim 7 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

12. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 143R, and L2 comprises amino acid substitutions 124E and 133E.

13. The antigen binding polypeptide construct of claim 12 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer, and wherein the Fc is a human Fc.

14. The antigen binding polypeptide construct of claim 13 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

15. The antigen binding polypeptide construct of claim 14 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

16. The antigen binding polypeptide construct according to claim 12 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

17. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitutions 143E, 145T, and 179E, L1 comprises amino acid substitutions 124R and 178R, H2 comprises amino acid substitution 186K, and L2 comprises amino acid substitutions 124E, 160E and 178E.

18. The antigen binding polypeptide construct of claim 17 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer, and wherein the Fc is a human Fc.

19. The antigen binding polypeptide construct of claim 18 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

20. The antigen binding polypeptide construct of claim 19 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

21. The antigen binding polypeptide construct according to claim 17 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

22. The antigen binding polypeptide construct of claim 1 , wherein H1 comprises amino acid substitutions 139C, 143E, 145T, and 179E, L1 comprises amino acid substitutions 116C, 124R and 178R, H2 comprises amino acid substitution 179K, and L2 comprises amino acid substitutions 124E, 160E and 180E.

23. The antigen binding polypeptide construct of claim 22 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer, and wherein the Fc is a human Fc.

24. The antigen binding polypeptide construct of claim 23 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

25. The antigen binding polypeptide construct of claim 24 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

26. The antigen binding polypeptide construct according to claim 22 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

27. The antigen binding polypeptide construct of claim 1 , wherein the antigen binding polypeptide construct further comprises an Fc comprising a first CH3 sequence and a second CH3 sequence, and a first CH2 sequence and a second CH2 sequence, and wherein the Fc is coupled, with or without one or more linkers, to the first heterodimer and to the second heterodimer.

28. The antigen binding polypeptide construct of claim 27 , wherein the Fc is a human Fc.

29. The antigen binding polypeptide construct of claim 28 , wherein the human Fc is a heterodimeric Fc.

30. The antigen binding polypeptide construct of claim 29 , wherein the human Fc comprises one or more substitutions in at least one of the CH3 sequences that promote the formation of a heterodimeric Fc with stability comparable to a wild-type homodimeric Fc.

31. The antigen binding polypeptide construct of claim 30 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide;

wherein the numbering of amino acid residues in the CH3 sequence is according to the EU numbering system.

32. The antigen binding polypeptide construct of claim 27 , wherein the first CH2 sequence and the second CH2 sequence comprise mutations that selectively alter the affinity of the Fc for Fcgamma receptors.

33. The antigen binding polypeptide construct of claim 27 , wherein the Fc is coupled to H1 and H2 by one or more linkers.

34. The antigen binding polypeptide construct according to claim 1 , wherein the antigen binding polypeptide construct is multispecific or bispecific.

35. The antigen binding polypeptide construct according to claim 27 , wherein the antigen binding polypeptide construct is conjugated to a therapeutic agent.

36. A pharmaceutical composition comprising the antigen binding polypeptide construct of claim 1 and a pharmaceutically acceptable carrier.

37. An isolated polynucleotide or set of isolated polynucleotides comprising at least one sequence that encodes the antigen binding polypeptide construct according to claim 1 .

38. A vector or set of vectors comprising one or more of the polynucleotides or sets of polynucleotides according to claim 37 .

39. An isolated cell comprising the polynucleotide or set of polynucleotides according to claim 37 .

40. A method of obtaining an antigen binding polypeptide construct from the isolated cell of claim 39 , the method comprising the steps of:

(a) obtaining a host cell culture comprising the isolated cell comprising one or more nucleic acid sequences encoding the antigen binding polypeptide construct; and

(b) recovering the antigen binding polypeptide construct from the host cell culture.

Assignments (4)
CHANGE OF NAME Recorded Apr 21, 2023
From: ZYMEWORKS INC.
To: ZYMEWORKS BC INC.
Reel/Frame 063400/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: SANCHES, MARIO; SPRETER VON KREUDENSTEIN, THOMAS
To: ZYMEWORKS INC.
Reel/Frame 059133/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: SANCHES, MARIO; SPRETER VON KREUDENSTEIN, THOMAS
To: ZYMEWORKS INC.
Reel/Frame 059133/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: CHOU, YANG-CHIEH; CORPER, ADAM LOUIS; D'ANGELO, IGOR EDMONDO PAOLO; DIXIT, SURJIT BHIMARAO; SANCHES, MARIO; SPRETER VON KREUDENSTEIN, THOMAS; TOM-YEW, STACEY A.L.; UROSEV, DUNJA
To: ZYMEWORKS INC.
Reel/Frame 059133/0705 →
Continuity (4)
Division 15314496
Provisional Application 62154055 · Apr 28, 2015
Provisional Application 62003663 · May 28, 2014
Related Publication 20220251242A1 · Aug 11, 2022
References Cited (231)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7642228B2 · Carter et al. · 2010 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8501185B2 · Heitner Hansen et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 9499634B2 · Dixit et al. · 2016 [cited by applicant]
US 9527927B2 · Chowdhury et al. · 2016 [cited by applicant]
US 9562109B2 · Von Kreudenstein et al. · 2017 [cited by applicant]
US 9574010B2 · Spreter Von et al. · 2017 [cited by applicant]
US 9708388B2 · Dutalys · 2017 [cited by applicant]
US 9771573B2 · Ohrn et al. · 2017 [cited by applicant]
US 9914785B2 · Corper et al. · 2018 [cited by applicant]
US 10077298B2 · Corper · 2018 [cited by examiner]
US 11078296B2 · Corper · 2021 [cited by applicant]
US 11161915B2 · Urosev et al. · 2021 [cited by applicant]
US 11286293B2 · Corper · 2022 [cited by examiner]
US 11306156B2 · Sanches · 2022 [cited by applicant]
US 20030003502A1 · Jardetzky et al. · 2003 [cited by applicant]
US 20030129659A1 · Whelihan et al. · 2003 [cited by applicant]
US 20050069549A1 · Herman · 2005 [cited by applicant]
US 20060160184A1 · Hoogenboom · 2006 [cited by applicant]
US 20070196363A1 · Arathoon et al. · 2007 [cited by applicant]
US 20070274985A1 · Dubel et al. · 2007 [cited by applicant]
US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]
US 20090162360A1 · Klein et al. · 2009 [cited by applicant]
US 20090182127A1 · Kjaergaard et al. · 2009 [cited by applicant]
US 20090232811A1 · Klein et al. · 2009 [cited by applicant]
US 20090263392A1 · Igawa et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100075326A1 · Jin et al. · 2010 [cited by applicant]
US 20100105874A1 · Schuurman et al. · 2010 [cited by applicant]
US 20100256338A1 · Brinkmann et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20100322934A1 · Imhof-Jung et al. · 2010 [cited by applicant]
US 20100322935A1 · Croasdale et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110008345A1 · Ashman et al. · 2011 [cited by applicant]
US 20110275787A1 · Kufer et al. · 2011 [cited by applicant]
US 20110287009A1 · Scheer et al. · 2011 [cited by applicant]
US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]
US 20120143580A1 · Constantine et al. · 2012 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20120244578A1 · Kannan et al. · 2012 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130195849A1 · Spreter Von et al. · 2013 [cited by applicant]
US 20130336973A1 · Spreter Von et al. · 2013 [cited by applicant]
US 20140051835A1 · Dixit et al. · 2014 [cited by applicant]
US 20140072581A1 · Dixit et al. · 2014 [cited by applicant]
US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]
US 20140187753A1 · Blein et al. · 2014 [cited by applicant]
US 20140200331A1 · Corper et al. · 2014 [cited by applicant]
US 20140370020A1 · Kuramochi et al. · 2014 [cited by applicant]
US 20150211001A1 · Ohrn et al. · 2015 [cited by applicant]
US 20150284470A1 · Spreter Von et al. · 2015 [cited by applicant]
US 20150307594A1 · Corper et al. · 2015 [cited by applicant]
US 20160257763A1 · Von Kreudenstein et al. · 2016 [cited by applicant]
US 20180179296A1 · Corper et al. · 2018 [cited by applicant]
US 20190085055A1 · Corper et al. · 2019 [cited by applicant]
US 20190338048A1 · Urosev et al. · 2019 [cited by applicant]
CN 1176659 · 1998 [cited by applicant]
CN 102153650 · 2012 [cited by applicant]
CN 104114579 · 2014 [cited by applicant]
CN 108283001A · 2018 [cited by applicant]
EP 1870459 · 2007 [cited by applicant]
EP 2543680 · 2013 [cited by applicant]
EP 2647707 · 2013 [cited by applicant]
JP 2012512894A · 2012 [cited by applicant]
JP 2012525149A · 2012 [cited by applicant]
JP 2018162253A · 2018 [cited by applicant]
WO 9404690 · 1994 [cited by applicant]
WO 9627011 · 1996 [cited by applicant]
WO 2006106905 · 2006 [cited by applicant]
WO 2007110205 · 2007 [cited by applicant]
WO 2008131242 · 2008 [cited by applicant]
WO 2009089004 · 2009 [cited by applicant]
WO 2010085682 · 2010 [cited by applicant]
WO 2010115553 · 2010 [cited by applicant]
WO 2011028952 · 2011 [cited by applicant]
WO 2011063348 · 2011 [cited by applicant]
WO 2011119484 · 2011 [cited by applicant]
WO 2011131746 · 2011 [cited by applicant]
WO 2011143545 · 2011 [cited by applicant]
WO 2011133886 · 2011 [cited by applicant]
WO 2011147982 · 2011 [cited by applicant]
WO 2012006635 · 2012 [cited by applicant]
WO 2012020096 · 2012 [cited by applicant]
WO 2012023053 · 2012 [cited by applicant]
WO 2012058768 · 2012 [cited by applicant]
WO 2012073985 · 2012 [cited by applicant]
WO 2012131555 · 2012 [cited by applicant]
WO 2012143523 · 2012 [cited by applicant]
WO 2013002362 · 2013 [cited by applicant]
WO 2013005194 · 2013 [cited by applicant]
WO 2013063702 · 2013 [cited by applicant]
WO 2013096291 · 2013 [cited by applicant]
WO 2013166594 · 2013 [cited by applicant]
WO 2014004586 · 2014 [cited by applicant]
WO 2014012082 · 2014 [cited by applicant]
WO 2014018572 · 2014 [cited by applicant]
WO 2014005784 · 2014 [cited by applicant]
WO 2014081955 · 2014 [cited by applicant]
WO WO2014082179 · 2014 [cited by examiner]
WO 2014124326 · 2014 [cited by applicant]
WO 2014150973 · 2014 [cited by applicant]
WO 20140150973 · 2014 [cited by applicant]
WO 2014182970 · 2014 [cited by applicant]
WO 2015006749 · 2015 [cited by applicant]
WO 2015173756 · 2015 [cited by applicant]
WO 2015181805 · 2015 [cited by applicant]
WO 2016026943 · 2016 [cited by applicant]
WO 2016172485 · 2016 [cited by applicant]
WO 2017059551 · 2017 [cited by applicant]
U.S. Appl. No. 13/927,065, Final Office Action mailed on Feb. 22, 2016, 6 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Non-Final Office Action mailed on Oct. 7, 2015, 10 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Notice of Allowance mailed on Aug. 26, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 13/927,065, Restriction Requirement mailed on Apr. 15, 2015, 9 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Final Office Action mailed on Dec. 29, 2016, 46 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Non-Final Office Action mailed on Sep. 10, 2015, 33 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Notice of Allowance mailed on Nov. 1, 2017, 10 pages. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement dated May 12, 2016. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement mailed on Jun. 18, 2015, 5 pages. [cited by applicant]
U.S. Appl. No. 14/432,153, Non-Final Office Action mailed on Oct. 27, 2016, 10 pages. [cited by applicant]
U.S. Appl. No. 14/432,153, Corrected Notice of Allowability mailed on Aug. 18, 2017, 7 pages. [cited by applicant]
U.S. Appl. No. 14/432,153, Notice of Allowance mailed on May 15, 2017, 8 pages. [cited by applicant]
U.S. Appl. No. 14/432,153, Restriction Requirement mailed on Jun. 30, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Notice of Allowance mailed on May 8, 2018, 74 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Final Office Action mailed on Dec. 29, 2017, 12 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Non-Final Office Action mailed on May 16, 2017, 43 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement mailed on May 9, 2016, 14 pages. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement mailed on Dec. 2, 2016, 33 pages. [cited by applicant]
U.S. Appl. No. 15/355,019, Non-Final Action issued Jul. 21, 2017. [cited by applicant]
U.S. Appl. No. 15/355,019, Notice of Allowance issued Nov. 17, 2017. [cited by applicant]
U.S. Appl. No. 15/355,019: Non-Final Office Action dated Jan. 8, 2019, 5 pages. [cited by applicant]
U.S. Appl. No. 15/355,019, Notice of Allowance dated Jul. 29, 2019. [cited by applicant]
U.S. Appl. No. 15/765,574, Restriction Requirement dated Sep. 10, 2019. [cited by applicant]
U.S. Appl. No. 15/765,574, Office Action dated Dec. 27, 2019. [cited by applicant]
U.S. Appl. No. 15/765,574, Notice of Allowance dated Sep. 2, 2020. [cited by applicant]
U.S. Appl. No. 15/896,170, Final Office Action dated May 18, 2020. [cited by applicant]
U.S. Appl. No. 15/896,170 Restriction Requirement dated Jun. 26, 2019. [cited by applicant]
U.S. Appl. No. 15/896,170 Office Action dated Sep. 18, 2019. [cited by applicant]
U.S. Appl. No. 16/122,417 Restriction Requirement dated Mar. 6, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417 Office Action dated Jun. 19, 2020. [cited by applicant]
Atwell et al., Stable Heterodimers From Remodeling the Domain Interface of a Homodimer Using a Phage Display Library, Journal of Molecular Biology, vol. 270, No. 1, Jul. 4, 1997, pp. 26-35. [cited by applicant]
Barthelemy et al., Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human Vh Domains, J. Bioi. Chem., vol. 283, No. 6, Feb. 2008, pp. 3639-3654. [cited by applicant]
Beck et al., Strategies and Challenges for the Next Generation of Therapeutic Antibodies, Nature Reviews Immunology, vol. 10, No. 5, May 2010, pp. 345-352. [cited by applicant]
Bell et al., Differential Tumor-targeting Abilities of Three Single-domain Antibody Formats, Cancer Letters, vol. 289, No. 1, 2010, pp. 81-90. [cited by applicant]
Bolon et al., Specificity Versus Stability in Computational Protein Design, Proceedings of the National Academy of Sciences, vol. 102, No. 36, Sep. 6, 2005, pp. 12724-12749. [cited by applicant]
Carter et al., Humanization Of An Anti-p185HER2 Antibody For Human Cancer Therapy, Proc. Natl. Acad. Sci. USA, vol. 89, No. 10, 1992, pp. 4285-4289. [cited by applicant]
Carter, Introduction to Current and Future Protein Therapeutics: a Protein Engineering Perspective, Experimental Cell Research, vol. 317, No. 9, May 15, 2011, pp. 1261-1269. [cited by applicant]
Chames et al., Therapeutic Antibodies: Successes, Limitations and Hopes for the Future, British Journal of Pharmacology, vol. 157, No. 2, 2009, pp. 220-223. [cited by applicant]
Chen, et al., “Preferential Germline Usage and VH/VL Pairing Observed in Human Antibodies Selected by mRNA display”, [cited by applicant]
Colman, Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions, Research in Immunology, vol. 145, No. 1, Jan. 1994, pp. 33-36. [cited by applicant]
Coloma et al., Design and Production of Novel Tetravalent Bispecific Antibodies, Nature Biotechnology, vol. 15, No. 2, Feb. 1997, pp. 159-163. [cited by applicant]
Dall'Acqua et al., Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers, Biochemistry, American Chemical Society, vol. 37, No. 26, Jun. 30, 1998, pp. 9266-9273. [cited by applicant]
Davis et al., SEEDbodies: Fusion Proteins Based on Strand-exchange Engineered Domain (SEED) CH3 Heterodimers in an Fc Analogue Platform for Asymmetric Binders or Immunofusions and Bispecific Antibodies, Protein Engineer… [cited by applicant]
Demarest et al., Antibody Therapeutics, Antibody Engineering, and the Merits of Protein Stability, Current Opinion in Drug Discovery and Development vol. 11, No. 5, Sep. 2008, pp. 675-687. [cited by applicant]
Demarest et al., Optimization of the Antibody CH3 Domain by Residue Frequency Analysis of IgG Sequences, Journal of Molecular Biology, vol. 335, No. 1, Jan. 2, 2004, pp. 41-48. [cited by applicant]
Fischer, N., et al., Exploiting light chains for the scalable generation and platform purification or native human bispecific IgG. Nature Communications, Feb. 12, 2015; 6(6113):1-12. [cited by applicant]
Gramer, M. J., et al., Production of stable bispecific lgG1 by controlled Fab-arm exchange. mAbs, Nov./Dec. 2013; 5(6):962-973. [cited by applicant]
Gunasekaran et al., Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG mailed on J. Biol. Chem., vol. 285, No. 25, Jun. 18, 2010, … [cited by applicant]
Hamel et al., The Role of the VL- and VH-Segments in the Preferential Reassociation of Immunoglobulin Subunits, Molecular Immunology, vol. 23, No. 5, May 23, 1986, pp. 503-510. [cited by applicant]
Head, et al., ‘Relative Stabilities of IgG1 and IgG4 Fab Domains Influence of the Light Heavy interchain disulfide bond arthiture’, [cited by applicant]
Holt et al., Domain Antibodies: Proteins for Therapy, Trends In Biotechnology vol. 21, No. 11, Nov. 2003, pp. 484-490. [cited by applicant]
Huang et al., A De Novo Designed Protein Protein Interface, Protein Science, vol. 16, No. 12, 2007, pp. 2770-2774. [cited by applicant]
Igawa et al., VH/VL Interface Engineering to Promote Selective Expression and Inhibit Conformational Isomerization of Thrombopoietin Receptor Against Single-chain Diabody, Protein Engineering, Design & Selection, vol. 2… [cited by applicant]
Jackman et al., Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling, J Biol Chem., vol. 285, No. 27, Jul. 2, 2010, pp. 20850-20859. [cited by applicant]
Jordan et al., Structural Understanding of Stabilization Patterns in Engineered Bispecific Ig-like Antibody Molecules, proteins: structure. Function. And bioinformatics, vol. 77, No. 4, Dec. 1, 2009, pp. 832-841. [cited by applicant]
Kabat, E.A., et al., ‘Sequences of proteins of Immunological Interest’, . Diae publishing, 5th Ed., vol. 1, 1991, NIH Publication 91-3242 (pp. 647-657, 661-669). [cited by applicant]
Klein et al., Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric LgG Antibodies, Mabs, vol. 4, No. 6, Nov. 2012, pp. 653-663. [cited by applicant]
Labrijin, A.F., et al., Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. PNAS. Mar. 26, 2016;110(13):5145-5150. [cited by applicant]
Lewis et al., Generation of Bispecific IgG Antibodies by Structure-Based Design of an Orthogonal Fab Interface, Nature Biotechnology, vol. 32, No. 2, Jan. 26, 2014, pp. 191-198. [cited by applicant]
Lindhofer et al., Preferential Species-restricted Heavy/light Chain Pairing in Rat/mouse Quadromas. Implications for a Single-step Purification of Bispecific Antibodies, The Journal of Immunology, vol. 155, No. 1, Jul. … [cited by applicant]
Liu, Zhi, et al., “A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism”, Journal of Biological Chemistry, vol. 290, No. 12, Mar. 2015, … [cited by applicant]
Lu et al., Fab-scFv Fusion Protein: an Efficient Approach to Production of Bispecific Antibody Fragments mailed on Journal of Immunological Methods, vol. 267, No. 2, 2002, pp. 213-226. [cited by applicant]
MacCallum et al., Antibody-antigen Interactions: Contact Analysis and Binding Site Topography, Journal of Molecular Biology, vol. 262, No. 5, Oct. 1996, pp. 732-745. [cited by applicant]
Marqusee et al., Helix Stabilization by Glu- . . . Lys+ Salt Sridges in Short Septides of De Novo Design, Proc Natl Acad Sci U S A., vol. 84, No. 24, 1987, pp. 8898-8902. [cited by applicant]
McCann et al., Peptide Tags for Labeling Membrane Proteins in Live Cells with Multiple Fluorophores, Bio Techniques, vol. 38, No. 6, Jun. 2005, pp. 945-951. [cited by applicant]
Merchant et al., An Efficient Route to Human Bispecific IgG, Nature Biotechnology, vol. 16, No. 7, Jul. 16, 1998, pp. 677-681. [cited by applicant]
Merk et al., Cell-Free Expression of Two single-Chain Monoclonal Antibodies against Lysozyme: Effect of Domain Arrangement on the Expression, J. Biochem., vol. 125, Dec. 31, 1999, pp. 328-333. [cited by applicant]
Miller et al., Stability Engineering of scFvs for the Development of Bispecific and Multivalent Antibodies, Protein Engineering. Design and selection, Oxford Journal, vol. 23, No. 7., Jul. 1, 2010, pp. 549-557. [cited by applicant]
Milstein et al., Hybrid Hybridomas and Their Use in Immunohistochemistry, Nature, vol. 305, No. 6, Oct. 6, 1983, pp. 537-540. [cited by applicant]
Moore et al., A Novel Bispecific Antibody Format Enables Simultaneous Bivalent and Monovalent Co-engagement of Distinct Target Antigens, mAbs, vol. 3, No. 6, 2011, pp. 546-557. [cited by applicant]
Omidfar et al., Single Domain Antibodies: a New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting, DNA Cell Biol., vol. 31, No. 6, 2012, pp. 1015-1026. [cited by applicant]
International Application No. PCT/IB2015/054107, International Preliminary Report on Patentability. [cited by applicant]
Padlan, E.A., et al., Antibody Fab assembly: the interface residues between CH1 and CL. Mol Immunol. Sep. 1986; 23(9):951-960. [cited by applicant]
Portolano et al., Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain “Roulette”, J Immunol., vol. 150, No. 3, Feb. 1, 1993, pp. 880-887. [cited by applicant]
Presta, et al., Engineering Therapeutic Antibodies for Improved Function, Biochem. Soc. Trans., vol. 30, No. 4, Aug. 2002, pp. 487-490. [cited by applicant]
Ridgway et al., Knobs-into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization, Protein Engineering, vol. 9, No. 7, Jul. 1996, pp. 617-621. [cited by applicant]
Robinson et al., Targeting ErbB2 and ErbB3 With a Bispecific Single-chain Fv Enhances 1-5 Targeting Selectivity and Induces a Therapeutic Effect in Vitro, Br. J. Cancer, vol. 99, Oct. 7, 2008, pp. 1415-1425. [cited by applicant]
Rudikoff et al., Single Amino Acid Substitution altering Antigen-binding Specificity, Proc. Natl Acad Sci., vol. 79,No. 6, 1982, pp. 1979-1983. [cited by applicant]
Schaefer, W., et al., Immunoglobulin domain crossover as a generic approach for the production of bispcific IgG antibodied. PNAS, Jul. 5, 2011; 108(27):11187-11192. [cited by applicant]
Schlatter et al., On the Optimal ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells, Biotechnology Progress, vol. 21, No. 1, Jan.-Feb. 2005, pp. 122-133. [cited by applicant]
Segal et al., Introduction: Bispecific Antibodies, Journal of Immunological Methods, vol. 248, No. 1-2, Feb. 1, 2001, pp. 1-6. [cited by applicant]
Spreter Von Kreudenstein, T., et al., Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering. Methods. Jan. 1, 2014; 65(1):77-94. [cited by applicant]
Stanglmaier et al., Bi20 (fBTA05), a Novel Trifunctional Bispecific Antibody (Anti-CD20 X Anti-CD3), Mediates Efficient Killing of B-cell Lymphoma Cells Even With Very Low CD20 Expression Levels, International Journal o… [cited by applicant]
Strop, P. J., et al., Generating Bispecific Human IgG1 and IgG2 Antibodies from any Antibody Pair. J Mol Biol., Jul. 13, 2012; 420(3):204-219. [cited by applicant]
Suresh et al., Bispecific Monoclonal Antibodies From Hybrid Hybridomas, Methods in Enzymology, vol. 121, 1986, pp. 210-228. [cited by applicant]
Traunecker et al., Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells, EMBO Journal, vol. 10, No. 12, Dec. 1991, pp. 3655-3699. [cited by applicant]
Troise et al., Differential Binding of Human Immunoagents and Herceptin to the ErbB2 Receptor, FEBS Journal, vol. 275, No. 20, 2008, pp. 4967-4979. [cited by applicant]
Tu et al., Generation and Characterization of Chimeric Antibodies against NS3, NS4, NS5, and Core Antigens of Hepatitis C Virus, Clinical & Vaccine Immnology, Jun. 2010, pp. 1040-1047. [cited by applicant]
Vitetta et al., Considering Therapeutic Antibodies, Immunology, Science, 2006, vol. 313, No. 5785, 2006, pp. 308-309. [cited by applicant]
Von Kreudenstein et al., Improving biophysical properties of a bispecific antibody scaffold to aid developability, vol. 5, No. 5, Sep./Oct. 2013, pp. 646-654. [cited by applicant]
Von Kreudenstein et al., Protein Engineering and The Use of Molecular Modeling and Simulation: The Case of Heterodimeric Fc Engineering, Methods, vol. 65, No. 1, Jan. 1, 2014, pp. 77-94. [cited by applicant]
Wiens et al., Mutation of a Single Conserved Residue in VH Complementarity-determining Region 2 Results in a Severe Ig Secretion Defect., J Immunology, vol. 167, No. 4, Aug. 2001, pp. 2179-2186. [cited by applicant]
Woods et al., LC-MS Characterization and Purity Assessment of a Prototype Bispecific Antibody, MABS, vol. 5, No. 5, Sep. 1, 2013, pp. 711-722. [cited by applicant]
Wu et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, Journal of Molecular Biology, vol. 294, Nov. 1999, pp. 151-162. [cited by applicant]
Zhu et al., Remodeling Domain Interfaces to Enhance Heterodimer Formation, Protein Science, vol. 6, No. 4, Apr. 1997, pp. 781-788. [cited by applicant]
Edwards, et all, J Mol Biology, 334(1); 2003. [cited by applicant]
Lloyd, et al, Protein Engineering, Design & Selection 22: 159-168, 2009. [cited by applicant]
Briney et al., Nature 566: 393 (Year: 2019). [cited by applicant]
Piche-Nicholas etal., MABS 10(1): 81-94 (Year: 2018). [cited by applicant]
Spiess et al., Molecular Immunology 67: 95-106 (Year: 2015). [cited by applicant]
U.S. Appl. No. 17/343,198; Non-Final Office Action dated Sep. 27, 2023. [cited by applicant]
RU2020112916, “Office Action”, Sep. 1, 2023, 27 pages. [cited by applicant]
JP2022-186638, “Office Action”, Oct. 25, 2023, 4 pages. [cited by applicant]
Berry, et al., “Substitution of Cysteine for Selenocysteine in Type I Iodothyronine Deiodinase Reduces the Catalytic Efficiency of the Protein but Enhances Its Translation”, Endocrinology, vol. 131, No. 4, Oct. 1992, pp… [cited by applicant]
Chen, et al., “Fusion Protein Linkers: Property, Design and Functionality”, Advanced Drug Delivery Reviews, vol. 65, No. 10, Oct. 15, 2013, pp. 1357-1369. [cited by applicant]
Halin, et al., “Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor Alpha”, Cancer Research, vol. 63, No. 12, Jun. 15, 2003, pp. 3202-3210. [cited by applicant]
Lund, et al., “Oligosaccharide-Protein Interactions in IgG can Modulate Recognition by Fcγ Receptors”, The FASEB Journal, vol. 9, No. 1, Jan. 1995, pp. 115-119. [cited by applicant]
Maeda, et al., “Engineering of Functional Chimeric Protein Gvargula Luciferase”, Analytical biochemistry, vol. 249, No. 2, Jul. 1997, pp. 147-152. [cited by applicant]
Mariuzza, et al., “The Structural Basis of Antigen-Antibody Recognition”, Annual Review of Biophysics and Biophysical Chemistry, vol. 16, Jun. 1987, pp. 139-159. [cited by applicant]
Pan, et al., “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”, Cancer Cell, vol. 11, No. 1, Jan. 2007, pp. 53-67. [cited by applicant]
Riechmann, et al., “Reshaping Human Antibodies for Therapy”, Nature, vol. 332, No. 6162, Mar. 24, 1988, pp. 323-327. [cited by applicant]
Su, et al., “The Role of Antibody Vk Framework 3 Region Towards Antigen Binding: Effects on Recombinant Production and Protein L Binding”, Scientific Reports, vol. 7, No. 1, Jun. 2017, pp. 1-7. [cited by applicant]
Vajdos, et al., “Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, Journal of Molecular Biology, vol. 320, No. 2, Jul. 5, 2002, pp. 415-428. [cited by applicant]
Singer et al., Genes and genomes; Two vols. V. 1, Moscow, “Mir”, 1998, p. 63. [cited by applicant]